Genexine Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	2.8yrs

Actualizaciones recientes de la dirección

Recent updates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Jul 12

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

CEO

Genexine no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jungwon Woo	President & Director	2.8yrs	sin datos	0% ₩ 0
Neil K. Warma	President & Director	2.5yrs	sin datos	sin datos
Young-Chul Sung	Founder & Chairman of the Scientific Advisory Board	no data	sin datos	5.75% ₩ 15.4b
Sung-June Hong	Executive VP	no data	sin datos	sin datos
Jongsoo Lee	Senior Manager of IR & PR	no data	sin datos	sin datos
Hyun Jin Park	EVP of Corporate Development	2.8yrs	sin datos	sin datos
Jong Sup Park	Chief Medical Officer	5.7yrs	sin datos	sin datos
Jang Hee Lee	EVP of Operations	2.8yrs	sin datos	sin datos
Ki Yong Kim	SVP of Bio Research Institute	2.8yrs	sin datos	sin datos
Chul Jun Hyun	Auditor & Director	2.8yrs	sin datos	sin datos
Jaehyun Choi	Head of R&D	less than a year	sin datos	sin datos

2.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de A095700 se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jungwon Woo	President & Director	2.8yrs	sin datos	0% ₩ 0
Neil K. Warma	President & Director	2.5yrs	sin datos	sin datos
Young-Chul Sung	Founder & Chairman of the Scientific Advisory Board	2.8yrs	sin datos	5.75% ₩ 15.4b
Sung-June Hong	Executive VP	2.8yrs	sin datos	sin datos
Chul Jun Hyun	Auditor & Director	2.8yrs	sin datos	sin datos
Young-Jin Kim	Chairman of BOD	2.8yrs	sin datos	sin datos
Keon Pai Jin	Non-Executive Director	2.8yrs	sin datos	sin datos
Mijung Ahn	Member of Scientific Advisory Board	2.8yrs	sin datos	sin datos
Peter Laivins	Director	2.8yrs	sin datos	sin datos
Hyeok Jong Lee	Director	2.8yrs	sin datos	sin datos
Heeseop Shin	Member of Scientific Advisory Board	2.8yrs	sin datos	sin datos
Munseok Gang	Member of Scientific Advisory Board	2.8yrs	sin datos	sin datos

2.8yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de A095700 no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Genexine Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

No independent directors

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

Recent updates

New minor risk - Shareholder dilution

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

New minor risk - Revenue size

New minor risk - Share price stability

Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority (BPOM)

Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study

Ajinomoto Co., Inc. (TSE:2802) agreed to acquire remaining 25% stake in Ajinomoto Genexine Co., Ltd from Genexine, Inc. (KOSDAQ:A095700) for KRW 19.3 billion.

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for Advanced Cervical Cancer

Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

Genexine, Inc. has completed a Follow-on Equity Offering in the amount of KRW 82.044713 billion.

No independent directors

Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc., Annual General Meeting, Mar 29, 2021

New 90-day low: ₩94,300

Turret Capital Management Signs A Definitive License Agreement with Genexine, Inc

New 90-day low: ₩103,600

Genexine, Inc. and NeoimmuneTech, Inc. Releases Data for Their Phase 1B/2 Study of Gx-I7/Nt-I7 and Keytruda® in Patients with Triple-Negative Breast Cancer

New 90-day low: ₩104,000

New 90-day low: ₩109,500

Genexine, Inc. announced that it has received KRW 3.29761 billion in funding from Handok, Inc.

New 90-day high - ₩132,000

New 90-day high - ₩130,600

CEO

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad